Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Propamidine→

Propamidine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
104-32-5
Molecular formula
C17H20N4O2
Molecular weight
312.37 g/mol
Drug class
Aromatic diamidine antiseptictopical antimicrobial agent
Mechanism of action
Interacts with microbial nucleic acids and cellular components, disrupting essential microbial processes. The exact mechanism varies by organism and is not fully defined; topical use is limited to selected ocular and local infections.
Indications / reported uses
  • Topical treatment of selected superficial eye infections, including bacterial conjunctivitis, using authorised ophthalmic formulations; systemic infection indications should not be inferred

Sources: NHS — Propamidine isetionate eye drops · NLM MeSH — Propamidine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Propamidine Environmental Risk Assessment (ERA) (the Propamidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.